share_log

中國生物製藥：截至二零二四年二月二十九日止月份的股份發行人的證券變動月報表

SINO BIOPHARM: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024

香港交易所 ·  Feb 29 21:34
Summary by Moomoo AI
中國生物製藥有限公司於2024年3月1日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年2月29日的資料。報告顯示，公司的法定/註冊股本及已發行股份在2月份均無變動，維持在30,000,000,000股，每股面值0.025港元，總股本為750,000,000港元。此外，公司於2023年6月15日股東大會上獲採納的股份期權計劃，本月內無變動，結存數目為零。同時，公司的零息可轉換債券亦無本月內變動，總額維持在2,150,000歐元，對應的可轉換新股份數目為1,535,467股，轉換價為每股12.06港元。報告最後確認，所有證券發行均已獲得董事會授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
中國生物製藥有限公司於2024年3月1日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年2月29日的資料。報告顯示，公司的法定/註冊股本及已發行股份在2月份均無變動，維持在30,000,000,000股，每股面值0.025港元，總股本為750,000,000港元。此外，公司於2023年6月15日股東大會上獲採納的股份期權計劃，本月內無變動，結存數目為零。同時，公司的零息可轉換債券亦無本月內變動，總額維持在2,150,000歐元，對應的可轉換新股份數目為1,535,467股，轉換價為每股12.06港元。報告最後確認，所有證券發行均已獲得董事會授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
China Biopharmaceuticals Limited filed with Hong Kong Trading and Settlement Limited on 1 March 2024 with Hong Kong Trading and Settlement Limited, covering data for the year ended 29 February 2024. The report shows that the company's regulated/registered share capital and issued shares remained unchanged in February at 30,000,000,000 shares with a face value of HK$0.025 per share and a total share capital of HK$750,000,000. In addition, the share option plan adopted at the Company's Annual General Meeting on 15 June 2023 was unchanged during the month and the number of deposits was zero. AT THE SAME TIME, THE COMPANY'S ZERO-YIELDING CONVERTIBLE BONDS REMAINED UNCHANGED DURING THE MONTH. THE TOTAL AMOUNT REMAINED AT EUR 2,150,000 AND THE CORRESPONDING NUMBER OF NEW CONVERTIBLE SHARES WAS 1,535,467 SHARES, WITH A CONVERSION PRICE OF HK$12.06 PER SHARE. THE REPORT FINALLY CONFIRMS THAT ALL SECURITIES ISSUANCE HAS BEEN AUTHORISED BY THE BOARD AND COMPLIES WITH THE RELEVANT REQUIREMENTS OF THE SECURITIES LISTING RULES OF THE HONG KONG STOCK EXCHANGE LIMITED.
China Biopharmaceuticals Limited filed with Hong Kong Trading and Settlement Limited on 1 March 2024 with Hong Kong Trading and Settlement Limited, covering data for the year ended 29 February 2024. The report shows that the company's regulated/registered share capital and issued shares remained unchanged in February at 30,000,000,000 shares with a face value of HK$0.025 per share and a total share capital of HK$750,000,000. In addition, the share option plan adopted at the Company's Annual General Meeting on 15 June 2023 was unchanged during the month and the number of deposits was zero. AT THE SAME TIME, THE COMPANY'S ZERO-YIELDING CONVERTIBLE BONDS REMAINED UNCHANGED DURING THE MONTH. THE TOTAL AMOUNT REMAINED AT EUR 2,150,000 AND THE CORRESPONDING NUMBER OF NEW CONVERTIBLE SHARES WAS 1,535,467 SHARES, WITH A CONVERSION PRICE OF HK$12.06 PER SHARE. THE REPORT FINALLY CONFIRMS THAT ALL SECURITIES ISSUANCE HAS BEEN AUTHORISED BY THE BOARD AND COMPLIES WITH THE RELEVANT REQUIREMENTS OF THE SECURITIES LISTING RULES OF THE HONG KONG STOCK EXCHANGE LIMITED.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more